AstraZeneca Signs an Agreement with Symbiosis for Sterile Manufacturing of its AZD1222 Against COVID-19

Shots:

• Symbiosis will provide AstraZeneca access to its sterile vaccine drug product manufacturing capacity for clinical trial supply
• The agreement follows AstraZeneca’s licensing agreement with the University of Oxford for the global development, manufacturing, and distribution of the AZD1222 vaccine candidate. The vaccine candidate is currently in clinical trials at multiple sites in the UK
•  Symbiosis will deploy its expertise and competitive strengths to accelerate the development of AstraZeneca’s vaccine and added value to the project

Click here to read full press release/ article | Ref: Symbiosis | Image: Symbiosis

Related News: AstraZeneca Signs an Agreement with Cobra Biologics for Vaccines Against COVID-19